StockMirror — Stock Screener

THYROCARE Q4 FY26 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Thyrocare delivered a strong Q4 FY26 with 20.4% YoY revenue growth, 31% EBITDA growth, and 128% PAT growth, driven by volume (29% YoY test growth) and gross margin expansion (113 bps YoY). Management guided for mid-to-high teens revenue growth in FY27, with a focus on specialty expansion (genomics, allergy) as a new growth pillar. They maintained a disciplined margin strategy (EBITDA ~34% stable), reinvesting any upside into growth while protecting base profitability. The asset-light franchise model (10,800+ franchisees) continues to scale. Risks include potential reagent cost inflation from forex and the early-stage nature of specialty investments. Balance sheet is strong with zero debt and INR230 cr+ net cash. , , , ,

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management explicitly follows a 'first margin protection, then growth' philosophy (Warren Buffett-like). They preserve base margins (EBITDA ~34%) and reinvest any operating leverage from growth into new initiatives (genomics, specialty) while protecting profitability. ,

About Thyrocare Technologies Limited

Thyrocare Technologies Limited (THYROCARE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More